Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSJ-0011 vs Urinary hCG for Ovulation Induction in Japanese Women
NCT01653743Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2012
- Primary completion
- Nov 2014
- Modality
- rProtein (Recombinant Protein), Hormone, Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of choriogonadotropin alfa in anovulation and Oligo-ovulation (2 arms), sponsored by Merck KGaA. Primary endpoint: Percentage of Subjects With Ovulation. Started Sep 2012; status: completed.
02
Drugs
choriogonadotropin alfa
03
Conditions
anovulationOligo-ovulation
Beyond the preview
Go deeper on NCT01653743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01653743.